5. References

  1. Chan C, Frei-Jones M. Sickle Cell Disease. In: DiPiro JT, Yee GC, Posey L, Haines ST, Nolin TD, Ellingrod V. eds. Pharmacotherapy: a pathophysiologic approach, 11e New York, NY: McGraw-Hill. Available from: http://accesspharmacy.mhmedical.com.ezproxy.lib.utexas.edu/content.aspx?bookid=2577&sectionid=228902837. Accessed June 6, 2022.
  2. DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com.libproxy.uthscsa.edu/. Accessed June 6, 2022.
  3. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2022. Available at: http://www.clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed June 6, 2022.
  4. Facts and Comparisons eAnswers [database online]. Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2022. Available at:  https://fco-factsandcomparisons-com.ezproxy.lib.utexas.edu. Accessed June 9, 2022.
  5. Lexicomp Online, Lexi-Drugs Online, Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2022. Available at: https://online-lexi-com.ezproxy.lib.utexas.edu/lco/action/home. Accessed June 6, 2022.
  6. Hydroxyurea (Droxia®) package insert. E.R. Squibb & Sons, L.L.C., August 2021.
  7. Hydroxyurea (Siklos®) package insert. Medunik. December 2021.
  8. L-glutamine (Endari®) package insert. Emmaus Medical, Inc., October 2020.
  9. Voxelotor (Oxbryta®) package insert. Global Blood Therapeutics Inc., December 2021.
  10. Lexicomp Online, Pediatric and Neonatal Lexi-Drugs Online, Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2022. Available at:  https://online-lexi-com.ezproxy.lib.utexas.edu/lco/action/home. Accessed June 7, 2022.
  11. Niihara Y, Miller ST, Kanter J, et al. Investigators of the phase 3 trial of l-glutamine in sickle cell disease. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018;379(3):226-235. [PubMed 30021096] 10.1056/NEJMoa1715971
  12. Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381:509-19. doi: 10.1056/NEJMoa1903212